Author:
Casole Giovanni,Ministrini Silvia,Gabella Federica,Tiberio Guido A. M.
Publisher
Springer Nature Switzerland
Reference16 articles.
1. Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476–90. Erratum in: Ann Oncol. 2023;34(7):631.
2. AIOM—Associazione Italiana di Oncologia Medica. Linee guida: neoplasie neuroendocrine, 2019 [Neuroendocrine neoplasms guidelines, 2019]. https://www.aiom.it/wp-content/uploads/2019/10/2019_LG_AIOM_Neuroendocrini.pdf.
3. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. Erratum in: J Clin Endocrinol Metab 2023 Apr 13;108(5):e200.
4. Zarnegar R, Kebebew E, Duh QY, Clark OH. Malignant pheochromocytoma. Surg Oncol Clin N Am. 2006;15(3):555–71.
5. Ellis RJ, Patel D, Prodanov T, et al. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg. 2013;217(3):489–96.